Personalis (NASDAQ:PSNL) Trading Down 4.8% – What’s Next?

Personalis, Inc. (NASDAQ:PSNL) shares were down 4.8% during mid-day trading on Friday . The stock traded as low as $8.38 and last traded at $8.4780. Approximately 194,504 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 1,274,530 shares. The stock had previously closed at $8.91.

Wall Street Analyst Weigh In

PSNL has been the subject of a number of recent research reports. BTIG Research boosted their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Lake Street Capital reissued a “buy” rating and set a $11.00 price objective on shares of Personalis in a report on Wednesday, November 5th. Morgan Stanley boosted their target price on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Guggenheim lifted their price objective on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Needham & Company LLC increased their target price on Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.86.

Personalis Trading Down 8.8%

The company has a market capitalization of $721.50 million, a PE ratio of -9.23 and a beta of 1.98. The firm’s 50-day simple moving average is $8.79 and its 200-day simple moving average is $7.81.

Insider Buying and Selling

In related news, CFO Aaron Tachibana sold 103,668 shares of Personalis stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the transaction, the chief financial officer owned 164,458 shares in the company, valued at approximately $1,772,857.24. This trade represents a 38.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 3.80% of the company’s stock.

Institutional Trading of Personalis

Several hedge funds have recently made changes to their positions in PSNL. Legal & General Group Plc acquired a new position in Personalis during the 2nd quarter worth $30,000. International Assets Investment Management LLC purchased a new stake in shares of Personalis in the fourth quarter valued at approximately $31,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Personalis in the second quarter valued at about $34,000. BNP Paribas Financial Markets boosted its position in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its position in Personalis by 184.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after buying an additional 3,592 shares during the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.